Literature DB >> 25126368

Are ACOs the Answer to High-Value Healthcare?

Wing Yeung1, Harrison Burns2, Deryk Loiacono3.   

Abstract

BACKGROUND: The Patient Protection and Affordable Care Act required the Secretary of the Department of Health and Human Services to establish the Medicare Shared Savings Program (MSSP) by January 1, 2012. The MSSP is intended to encourage physicians, hospitals, and other providers and suppliers to form accountable care organizations (ACOs) to provide cost-effective, coordinated care to Medicare beneficiaries. Under the MSSP, ACOs can qualify for additional payments by meeting specific savings benchmarks and quality measures.
OBJECTIVES: To review the anticipated changes in the role and responsibilities of ACOs and to evaluate the challenges and opportunities that various healthcare stakeholders, including patients, providers, and payers, will encounter with the launching of the new MSSP. DISCUSSION: ACOs assume responsibility for overall care, cost, and quality of patient care. The MSSP will provide ACOs additional payments for meeting cost-savings and quality benchmarks. The extra savings will be shared with participating providers based on different risk-sharing options. As the MSSP and new ACOs launch, stakeholders will be impacted differently. This article is based, in part, on responses of approximately 100 payers to a survey conducted in June 2011 by Xcenda. Each stakeholder group, including providers, payers, patients, and manufacturers, must monitor the reactions and relationships between all players in the care continuum. Providers will have to achieve a greater level of coordination and collaboration than typically exists today. Government and commercial payers will have a role in determining how quickly they will adopt accountable care models. Patients are expected to become more engaged and participatory in their care to achieve optimal outcomes, and manufacturers will be required to prove the value of their products given the clinical value proposition embedded in accountable care models.
CONCLUSION: Whether ACOs are the answer to providing higher-quality healthcare at lower costs remains unclear. All signs, however, point toward a systemic change in an effort to improve patient care and contain healthcare costs. It will be important for all healthcare stakeholders to understand the roles that ACOs will play in ensuring access to care and quality of care.

Entities:  

Year:  2011        PMID: 25126368      PMCID: PMC4106496     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN: 1942-2962


  5 in total

1.  Use of telemonitoring to decrease the rate of hospitalization in patients with severe congestive heart failure.

Authors:  M E Cordisco; A Benjaminovitz; K Hammond; D Mancini
Journal:  Am J Cardiol       Date:  1999-10-01       Impact factor: 2.778

2.  Medicare program; Medicare Shared Savings Program: Accountable Care Organizations. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2011-11-02

3.  Patients' role in accountable care organizations.

Authors:  Anna D Sinaiko; Meredith B Rosenthal
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

4.  Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention.

Authors:  Jean Bourbeau; Marcel Julien; François Maltais; Michel Rouleau; Alain Beaupré; Raymond Bégin; Paolo Renzi; Diane Nault; Elizabeth Borycki; Kevin Schwartzman; Ravinder Singh; Jean-Paul Collet
Journal:  Arch Intern Med       Date:  2003-03-10

5.  Self-management reduces both short- and long-term hospitalisation in COPD.

Authors:  M-A Gadoury; K Schwartzman; M Rouleau; F Maltais; M Julien; A Beaupré; P Renzi; R Bégin; D Nault; J Bourbeau
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

  5 in total
  1 in total

Review 1.  Can biosimilars help achieve the goals of US health care reform?

Authors:  Ralph Boccia; Ira Jacobs; Robert Popovian; Gilberto de Lima Lopes
Journal:  Cancer Manag Res       Date:  2017-06-01       Impact factor: 3.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.